The Long-term Effects of Oceanix™ on Resistance Training Adaptations

February 26, 2020 updated by: Applied Science & Performance Institute

The Long-term Effects of Oceanix™ Supplementation on Oxidative Stress, Performance, Body Composition and Safety Metrics

This study will examine the effects of Oceanix™, an antioxidant supplement, on muscle performance, immune and endocrine function, recovery and safety in participants undergoing resistance training. Measures of muscle performance will include isometric testing in the bench-press and mid-thigh pull and ground reaction forces in the counter movement- and squat-jump. Markers of immune function will include salivary immunoglobulin A (IgA) as well as serum total antioxidant capacity (TAC) and superoxide dismutase (SOD) while endocrine function will be measured by salivary cortisol and testosterone. Recovery will be measure by plasma creatine kinase (CK) and perceptual measures will be assessed using a validated perceived recovery status (PRS) scale. Safety metrics will be indicated by a comprehensive metabolic panel (CMP), complete blood count (CBC), and urinalysis (UA). Additionally, the modified Borg Rating of Perceived Exertion (RPE) will be administered following each training session to grade physical exertion and monitor progression of the training protocol.

Study Overview

Detailed Description

This study will examine the effects of Oceanix™, an antioxidant supplement, on muscle performance, immune and endocrine function, recovery and safety in participants undergoing resistance training. Measures of muscle performance will include isometric testing in the bench-press and mid-thigh pull and ground reaction forces in the counter movement- and squat-jump. Markers of immune function will include salivary immunoglobulin A (IgA) as well as serum total antioxidant capacity (TAC) and superoxide dismutase (SOD) while endocrine function will be measured by salivary cortisol and testosterone. Recovery will be measure by plasma creatine kinase (CK) and perceptual measures will be assessed using a validated perceived recovery status (PRS) scale. Safety metrics will be indicated by a comprehensive metabolic panel (CMP), complete blood count (CBC), and urinalysis (UA). Additionally, the modified Borg Rating of Perceived Exertion (RPE) will be administered following each training session to grade physical exertion and monitor progression of the training protocol.

This study will be a double blind parallel, randomized placebo-controlled trial. The investigators will request participation from 25 male and female participants (40-60 % mixture of each) ranging from 18 to 45 years old who are active (i.e. 30 minutes per week of vigorous activity classified as greater than 75 % of their HR max 3 days • week-1). The exclusion criteria will include having a BMI of 30 or more kg/m²; having cardiovascular, metabolic, or endocrine disease; undergone surgery that affects digestion and absorption, smoking, drinking heavily (> 7 and > 14 drinks per week for women and men, respectively), women who are pregnant or planning to be pregnant; taking medication to control blood pressure, lipids, and blood glucose; have taken or currently taking anabolic-androgenic steroids. The investigators will also exclude individuals using antioxidant supplements, NSAIDS, or nutritional supplements known to stimulate recovery or muscle mass gains, heart disease, prescription medications, dietary supplements that enhance body strength, muscle, immune function, muscle recovery, or soreness. Additionally, individuals cannot have allergies for seaweeds or marine sources or any dietary supplements or take any psychiatric supplements or blood thinners.

Participants will be baselined and post-tested at week zero and again after 6 weeks of training, respectively. However, on weeks 2 and 5, participants will experience an overreaching phase to induce stress, and run through specific tests to gauge recovery at the end of those specific weeks. Variables collected at these time points are described below.

Primary variables:

  • Muscle, fat mass, and bone density as indicated on DXA
  • Upper body strength, velocity, and power on the bench press.
  • Lower body strength and power on a dual force plate.
  • Vertical jump performance on a dual force plate.
  • Movement mechanics and stability using a combination of motion analysis and a dual force plate.

Secondary Variables

  • CBC, CMP, Urinalysis
  • Vital signs (blood pressure)
  • Adverse Events Scale
  • PRS and RPE scales

At the end of weeks 2 and 5 participants will be examined for their perceived recovery, soreness, serum markers of muscle damage (creatine kinase), and oxidative stress markers (SOD and Total Antioxidant Status). The rationale for the time points is to introduce extreme stressors in the early and late stages of the training protocol. Variables collected at these time points are described below.

Secondary variables

  • Muscle damage (blood creatine kinase), soreness, and recovery.
  • Immune function (IGA) , endocrine function (cortisol and testosterone), and oxidative stress (SOD and total antioxidant status).
  • PRS scale

Study Type

Interventional

Enrollment (Actual)

25

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Florida
      • Tampa, Florida, United States, 33607
        • Applied Science & Performance Institute

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Physically active males and females aged 18 to 45 years.
  • Volunteers are deemed active if they engage in 30 minutes of vigorous activity, classified as greater than 75 % of their HR max, 3 days • week-1.

Exclusion Criteria:

  • > BMI of 30 or more kg/m²
  • Cardiovascular, metabolic, or endocrine disease
  • Undergone surgery that affects digestion and absorption
  • Smoking
  • Drinking heavily (> 7 and > 14 drinks per week for women and men, respectively)
  • Women who are pregnant or planning to be pregnant
  • Taking medication to control blood pressure, lipids, and blood glucose
  • Have taken or currently taking anabolic-androgenic steroids
  • Individuals using antioxidant supplements, NSAIDS, or nutritional supplements known to stimulate recovery or muscle mass gains, heart disease, prescription medications, dietary supplements that enhance body strength, muscle, immune function, muscle recovery, or soreness
  • Allergies for seaweeds or marine sources

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a visually identical placebo (25mg hydroxypropyl methylcellulose) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Experimental: Oceanix™
Participants will engage in a 6 week, whole-body, resistance training program 3-5 days per week will consuming a the treatment condition (Oceanix™) 30 minutes prior to exercise on training days or with the first meal of the day on non-training days.
6 weeks of supervised and programmed whole body resistance training, performed 3-5 times per week.
Ingredient contains highly active antioxidant enzymes, including superoxide dismutase (SOD), as well as essential fatty acids, vitamins, amino acids and minerals.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in muscle strength
Time Frame: Pre, Week 2, Week 5, Week 6
Assessed by isometric mid-thigh pull and isometric bench-press
Pre, Week 2, Week 5, Week 6
Changes in muscle power
Time Frame: Pre, Week 2, Week 5, Week 6
Assessed through ground reaction forces during countermovement- and squat-jumps on a force plate.
Pre, Week 2, Week 5, Week 6
Total Antioxidant Capacity (TAC)
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining total antioxidant capacity in fasted whole blood samples. The TAC measures the overall collective power of the blood to neutralize free radicals.
Pre, Week 2, Week 5, Week 6
Superoxide Dimutase (SOD)
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining superoxide dimutase in fasted whole blood samples. This is another protective antioxidant enzyme measured from whole blood.
Pre, Week 2, Week 5, Week 6
Creatine Kinase (CK)
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining creatine kinase in fasted whole blood samples. This is biomarker an indirect measure of muscle damage.
Pre, Week 2, Week 5, Week 6
Body Composition
Time Frame: Pre and Week 6
Body Composition will be assessed via dual-energy x-ray absorptiometry (DXA). Using this method, changes in total-, lean-, and fat-mass will be examined.
Pre and Week 6

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rating of Perceived Exertion (RPE)
Time Frame: Following every resistance training session throughout the study.
Assessed through a visual analog scale (modified Borg Scale) numbered 0-10 with visual descriptors. For example, at 0 the descriptor is "rest" and at 10 the descriptor is "maximal exertion".
Following every resistance training session throughout the study.
Perceived Recovery Status (PRS)
Time Frame: Prior to every resistance training session throughout the study.
Assessed through a visual analog scale numbered 0-10 with visual descriptors. For example, at 0 the descriptor is "very poorly recovered/extremely tired" and at 10 the descriptor is "very well recovered/highly energetic".
Prior to every resistance training session throughout the study.
Immunoglobulin A (IgA)
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining the concentration of IgA in fasted saliva samples.
Pre, Week 2, Week 5, Week 6
Cortisol
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining the concentration of Cortisol in fasted saliva samples.
Pre, Week 2, Week 5, Week 6
Testosterone
Time Frame: Pre, Week 2, Week 5, Week 6
Experimental outcome examining the concentration of testosterone in fasted saliva samples.
Pre, Week 2, Week 5, Week 6
Complete Blood Count
Time Frame: Pre and Week 6
Complete blood count with differential will be assessed via fasted whole blood samples.
Pre and Week 6
Comprehensive Metabolic Panel
Time Frame: Pre and Week 6
Comprehensive metabolic panel will be assessed via fasted whole blood samples.
Pre and Week 6
Urinalysis
Time Frame: Pre and Week 6.
Urinalysis gross examinations will be conducted prior to and at the completion of the study (Week 6).
Pre and Week 6.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resting Systolic Blood Pressure
Time Frame: Pre and Week 6
Change in resting systolic blood pressure.
Pre and Week 6
Resting Diastolic Blood Pressure
Time Frame: Pre and Week 6
Change in resting diastolic blood pressure.
Pre and Week 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 30, 2019

Primary Completion (Actual)

November 15, 2019

Study Completion (Actual)

January 31, 2020

Study Registration Dates

First Submitted

October 16, 2019

First Submitted That Met QC Criteria

October 21, 2019

First Posted (Actual)

October 23, 2019

Study Record Updates

Last Update Posted (Actual)

February 27, 2020

Last Update Submitted That Met QC Criteria

February 26, 2020

Last Verified

February 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • ASPI0519

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe